Drug intelligence / Profile preview

cisplatin + methotrexate + mitomycin C + vinblastine

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of cisplatin, methotrexate, mitomycin C, and vinblastine. This four-drug combination has been studied primarily for the treatment of unresectable non-small cell lung cancer, showing an overall response rate of 54% with responses observed across various cancer subtypes including squamous cell, adenocarcinoma, and undifferentiated large cell lung cancer. The regimen works through multiple mechanisms: cisplatin damages DNA, methotrexate inhibits dihydrofolate reductase, mitomycin C cross-links DNA, and vinblastine interferes with microtubule formation.

Targets

TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)DNA

Beyond the preview

Go deeper on cisplatin + methotrexate + mitomycin C + vinblastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + methotrexate + mitomycin C + vinblastine.

Explore the full profile